Cefprozil-d4
目录号 : GC48593
An internal standard for the quantification of cefprozil
Cas No.:1426173-48-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefprozil-d4 is intended for use as an internal standard for the quantification of cefprozil by GC- or LC-MS. Cefprozil is an orally bioavailable, second generation, broad-spectrum cephalosporin antibiotic that inhibits the growth of both Gram-positive and Gram-negative bacteria.1,2 It inhibits the growth of E. coli, E. faecalis, E. faecium, N. gonorrhoeae, N. meningitidis, P. mirabilis, S. aureus, S. pyogenes, and S. pneumoniae strains (MICs = 0.013-25 μg/ml) and clinical isolates of penicillin-susceptible, -intermediate, and -resistant S. pneumoniae and methicillin-sensitive S. aureus (MIC90s = 0.12-16 μg/ml). In vivo, cefprozil protects mice challenged with E. coli, S. aureus, S. pyogenes, and P. mirabilis strains with protective doses (PD50s) ranging from 0.07 to 1.3 mg/kg.1 Cefprozil binds to penicillin-binding proteins (PBPs), which disrupts their ability to cross-link peptidoglycan and leads to weakened bacterial cell walls.3 Formulations containing cefprozil have been used in the treatment of respiratory tract, skin, and other bacterial infections.
1.Tomatsu, K., Ando, S., Masuyoshi, S., et al.In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporinJ. Antibiot. (Tokyo)40(8)1175-1183(1987) 2.Peric, M., Browne, F.A., Jacobs, M.R., et al.Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: Use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agentsClin. Ther.25(1)169-177(2003) 3.Nagai, K., Davies, T.A., Jacobs, M.R., et al.Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococciAntimicrob. Agents Chemother.46(5)1273-1280(2002)
| Cas No. | 1426173-48-9 | SDF | |
| Canonical SMILES | O=C(O)C1=C(/C=C/C)CS[C@@]([C@@H]2NC([C@H](N)C3=C([2H])C([2H])=C(O)C([2H])=C3[2H])=O)([H])N1C2=O | ||
| 分子式 | C18H15D4N3O5S | 分子量 | 393.5 |
| 溶解度 | DMSO: soluble,Methanol: soluble,Water: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5413 mL | 12.7065 mL | 25.413 mL |
| 5 mM | 0.5083 mL | 2.5413 mL | 5.0826 mL |
| 10 mM | 0.2541 mL | 1.2706 mL | 2.5413 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Development and Validation of an HPLC-MS/MS Method for Rapid Simultaneous Determination of Cefprozil Diastereomers in Human Plasma
Int J Anal Chem 2018 Sep 13;2018:6959761.PMID:30302091DOI:PMC6158942
Background: Both cis- and trans-cefprozil have antimicrobial activity, but their potencies are quite different. It is therefore necessary to develop a sensitive method to simultaneously determine both isomers for pharmacokinetic and bioequivalence studies. Methods: An LC-MS/MS method, using stable isotope-labeled cefprozil as the internal standard, was developed and validated. The analytes were extracted from plasma by protein precipitation and separated on a reverse-phase C18 column using a gradient program consisting of 0.5% formic acid and acetonitrile within 4 min. The mass spectrometry acquisition was performed with multiple reaction monitoring in positive ion mode using the respective [M+H]+ ions, m/z 391.2→114.0 for cefprozil and 395.0→114.5 for Cefprozil-d4. Results: The calibration curves were linear over the ranges of 0.025-15 μg/mL for cis-cefprozil and 0.014-1.67 μg/mL for trans-cefprozil. The accuracies for the cis and trans isomers of cefprozil were 93.1% and 103.0%, respectively. The intra- and interassay precisions for the QC samples of the isomers were < 14.3%. The intra- and interassay precisions at the LLOQ were < 16.5%. Conclusions: The method was sensitive and reproducible and was applied in a pilot pharmacokinetic study of healthy volunteers.